Aspire-202: A Phase 2 Multi-center, Randomized, Open-label Study to Assess the Efficacy and Safety of AHB-137 in Nucleos(t)ide Analogue-treated Participants with Chronic Hepatitis B in the North America and Europe Regions
Hepatitis B is a long-term viral infection of the liver. Current standard treatments, called antiviral tablets, work well to stop the virus from multiplying. However, they rarely clear the virus completely, meaning most people have to take tablets every day for life. The Aspire-202 study is testing a new investigational medicine called AHB-137. It is designed for adults who are already taking regular antiviral medication. Researchers want to see if AHB-137 can reduce key viral proteins to undetectable levels in the blood. The goal is to work towards what doctors call a 'functional cure'—where your own immune system keeps the virus controlled even without daily medication. The trial is open to adults aged 18 and over across Europe and North America. Doctors will carefully monitor participants' safety, liver health, and viral levels throughout the study.
At a glance
What is this study about?
Chronic hepatitis B is a persistent liver infection caused by the hepatitis B virus. Millions of people live with the condition worldwide. While modern daily antiviral tablets do a good job of keeping the virus quiet, they usually cannot get rid of it entirely. This means people generally have to stay on medication for life to protect their liver from damage.
The Aspire-202 clinical trial is exploring a new medicine called AHB-137. This experimental treatment works differently from standard tablets. It aims to dramatically reduce the amount of viral proteins in the bloodstream, particularly a marker called hepatitis B surface antigen (HBsAg). When levels of this protein drop, scientists hope it will give the body's natural immune system a chance to fight back.
The ultimate goal of this research is to achieve a 'functional cure'. This means the virus remains controlled at harmless, undetectable levels, and the liver stays healthy even after stopping daily antiviral medicine.
Because this is a Phase 2 clinical trial, researchers are testing both the effectiveness and the safety of AHB-137. Specialist doctors across Europe and North America will closely track how patients respond and ensure that any side effects are managed quickly.
Key takeaways
- The Aspire-202 trial tests a new medicine called AHB-137 for chronic hepatitis B.
- The aim is to help the immune system control the virus without lifelong daily tablets.
- Open to adults aged 18 and older who already take standard antiviral medicine.
- Participants receive close, regular health checks from liver specialists.
- Joining the study is completely voluntary, and you can withdraw at any time.
Who may be eligible?
This study is open to adults aged 18 and over who have chronic hepatitis B and are already taking standard antiviral tablets (such as entecavir or tenofovir).
To take part, you must have reasonably stable liver health and be willing to attend regular hospital appointments for check-ups and blood tests. Men and women can both join.
You may not be eligible if you have very advanced liver scarring (known as decompensated cirrhosis), other serious active infections, or other significant medical conditions. Women who are pregnant or breastfeeding are generally unable to take part. The study doctor will review your full medical history to confirm whether the trial is safe and appropriate for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am at least 18 years old.
- I have been diagnosed with chronic hepatitis B.
- I am currently taking daily antiviral tablets for hepatitis B.
- I am able and willing to attend regular hospital check-ups and give blood samples.
- I am not pregnant or planning a pregnancy during the trial period.
What does participation involve?
Taking part in this study involves regular visits to a specialist hospital clinic. During your visits, doctors will give you physical examinations, take blood and urine samples, and monitor your vital signs. You will receive the study drug, AHB-137, alongside your routine care. The medical team will check how your body processes the medicine and how your liver reacts. At certain stages, doctors may test whether it is safe to pause your daily antiviral tablets to see if your body can control the virus on its own. You will then have follow-up visits so doctors can keep checking your health. The study team will explain the full schedule and expected time commitment before you decide to take part.
Potential risks and benefits
Locations (3)
- —UnverifiedFrance
- —UnverifiedItaly
- —UnverifiedSpain
Common questions
What is a 'functional cure' for hepatitis B?
A functional cure means the virus is controlled at such low levels that routine tests cannot detect it, and your liver remains healthy without needing lifelong daily antiviral medicine.
Will I have to stop my current hepatitis B tablets?
You will start the trial while continuing your usual tablets. Doctors may consider stopping them at a later stage, but only under careful supervision if your blood tests show it is safe.
How is the study medicine given?
The trial doctor will explain the exact method, such as an injection, as well as how often you will receive it during your clinic appointments.
Does taking part cost anything?
No. The trial medicine, tests, and specialist visits are provided free of charge, and help with travel expenses is often available.
Can I leave the study if I change my mind?
Yes. You can leave the study at any time for any reason. Your decision will not change the quality of your usual NHS or specialist care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.